The starting age for high-risk HPV for primary screening for cervical cancer is 25 years and the ending age is 65 years. Triage management for those with positive high-risk HPV test results is as follows: 1. If HPV 16 or 18 is positive, colposcopy is directly recommended. 2. If the test is positive for other high-risk types, cytology is applied for triage. If the test result is ASC-US and above, colposcopy is performed directly; if the cytology test result is normal then follow-up is done at 12 months. The interval between re-screening for those with negative high-risk HPV test results is currently recommended to be 3 years. The main advantages of using HPV testing as a primary screening protocol for cervical cancer: 1. Compared with cytology primary screening, HPV testing primary screening has higher sensitivity, high sensitivity and high specificity for the diagnosis of CIN2 and above lesions. 2. HPV testing primary screening has higher negative predictive value, allowing for longer screening intervals and reduced screening costs. Of course, HPV testing as a primary screening program for cervical cancer screening has its shortcomings, mainly the relatively low specificity and low positive predictive value of HPV testing, which leads to increased psychological pressure and even trauma for the patient, and high colposcopy rate and even over-treatment.